Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 29, 2007

AAIPharma Incorporates Phase Forward Products

  • Under a multiyear contract, AAIPharma will offer services centered around two Phase Forward products as part of its solution set: the InForm™ Integrated Trial Management (ITM) electronic data capture (EDC) system and the Clintrial™ clinical data management product that can be used to collect, manage, and review electronically captured and paper-based study data. AAIPharma says that it selected these products because of their straightforward implementation requirements and intuitive interface, requiring very little training post-deployment. Another advantage is Phase Forward’s flexible partner program that will allow AAIPharma to expand and customize offerings at its own pace, according to Anne Wiles, senior vp, data systems and processes, AAIPharma. “As EDC adoption continues, it is important that we offer the technology that sponsors view as an industry standard, while also supporting those clients requiring a solution that supports both electronic and paper-based trials.”

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »